Burosumab/Calcitriol/Phosphate-replacements
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.
Top bar navigation
Review for "Burosumab for the Treatment of Tumor-Induced Osteomalacia"
Kontraindikation von Crysvita® (Burosumab)
Burosumab-related risk of severe hypercalcaemia
Burosumab-related AEs identified in FAERS